The FDA has approved the first-ever gene therapy for sickle cell disease, a landmark moment in the treatment of the inherited blood disorder. The therapy, which uses CRISPR gene-editing technology, offers the potential for a one-time cure for patients who have long suffered from the painful and debilitating condition. This approval marks a major milestone for gene therapy and offers new hope for individuals with other genetic diseases. However, the high cost of the treatment raises questions about access and affordability.
